Browsing Tag
Medicaid
20 posts
Why Trump’s public charge rule could reshape legal immigration and safety-net access
Trump’s public charge rule could affect green card applicants, Medicaid, food aid, housing benefits and immigrant families.
HCA Healthcare stock (NYSE: HCA) sinks 7.6% as uninsured costs force a 2026 reset
HCA Healthcare has reduced its 2026 profit outlook after rising uninsured volumes produced an estimated US$400 million second-quarter hit. With $HCA down sharply and trading near 12 times revised earnings, attention turns to the July 24 update.
Eli Lilly (LLY) drug access strategy puts pricing, Medicare and GLP-1 growth in focus
Find out how Eli Lilly’s drug access strategy could reshape LLY stock, GLP-1 pricing, Medicare coverage and pharma competition.
Why California’s healthcare fraud crackdown could become a major political test
Find out how California’s healthcare fraud crackdown could reshape taxpayer oversight, Medicaid scrutiny and political accountability today!
Lumos Diagnostics Holdings Limited puts FebriDx US rollout at centre of ASX:LDX rerating test
Find out how Lumos Diagnostics Holdings is using FebriDx US adoption to test whether ASX:LDX can turn regulatory wins into revenue.
Why Nebraska’s Medicaid work requirements rollout is now a national test case
Nebraska moved first on Medicaid work rules. The real test is whether eligibility systems can protect coverage while enforcing compliance.
What does Acadia Healthcare’s new board pick and Wall Street advisory team really signal for ACHC shareholders?
Acadia Healthcare (ACHC) appoints Tenet Healthcare CFO veteran Daniel Cancelmi to its board as Khrom Capital pressure grows. Read the full strategic analysis.
Firstsource (NSE: FSL) acquires TeleMedik to scale clinical AI services across U.S. health plans
Firstsource acquires TeleMedik to expand AI-powered clinical services for U.S. payers. Find out how this move reshapes healthcare outsourcing strategy.
GSK dodges tariffs with a massive pricing pivot—but what’s the catch?
GlaxoSmithKline cuts drug prices in the U.S. and secures tariff relief under a new federal deal. Find out what this means for pharma's future pricing playbook.
Why Bristol Myers Squibb is giving away Eliquis to Medicaid and what it signals for U.S. drug pricing next
Bristol Myers Squibb will offer Eliquis free to Medicaid under a U.S. pricing deal. Find out what it means for drug pricing, investors, and patients.